Models of mycoplasma respiratory and genital tract infections

Wiener Klinische Wochenschrift

Volumn 109, Issue 14-15, 1997, Pages 569-573

  Brunner, Helmut ^a,b  

^a BAYER AG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

experimental infections; models; mycoplasmas; therapy; ureaplasmas; vaccines

Indexed keywords

ERYTHROMYCIN; VACCINE;

CONFERENCE PAPER; GENITAL TRACT INFECTION; MODEL; MYCOPLASMA; RESPIRATORY TRACT INFECTION; UREAPLASMA;

ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; DOGS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; MICE; MYCOPLASMA INFECTIONS; RATS; RESPIRATORY TRACT INFECTIONS; UREAPLASMA INFECTIONS;

EID: 0030760838     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Mackaness GB (1971) Resistance to intracellular infections. J Infect Dis 123: 439-445
2. Dajani AI, Clyde WA Jr, Denny FW (1965) Experimental infection with Mycoplasma pneumoniae (Eaton-Agent). J Exp Med 121: 1071-1085
3. Lo S-C, Wear DJ, Shih J W-K, Wang R Y-H, Newton III PB, Rodriguez JF (1993) Fatal systemic infections of nonhuman primates by Mycoplasma fermentans (incognitus strain). Clin Infect Dis 17 [Suppl] 1: S283-S288
4. Montagnier L, Blanchard A (1993) Mycoplasmas as cofactors due to the human immunodeficiency virus. Clin Infect Dis 17 [Suppl] 1: S309-S315
5. Williams MH, Brostoff J, Roitt IM (1970) Possible role of Mycoplasma fermentans in pathogenesis of rheumatoid arthritis. Lancet ii: 277-280
6. Cole BC (1996) Mycoplasma interactions with the immune system: implications for disease pathology. ASM News 62: 471-475
7. Clyde WA (1993) Clinical overview of typical Mycoplasma pneumoniae infections. Clin Infect Dis 17 [Suppl] 1: S32-S36
8. Foy HM (1993) Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 17 [Suppl] 1: S37-S46
9. Lin Y, Collins JL, Case PC, Patek PQ (1988) Effect of mycoplasmas on natural cytotoxic activity and release of tumor necrosis factor alpha by spleen cells. Infect Immun 56: 3072-3075
10. Meseguer MA, Baquero F, Bricio MT (1996) Kinetics of TNF-α release by murine peritoneal macrophage cells stimulated with different preparations of Mycoplasma pneumoniae. IOM Letters 4: 144-145
11. Brunner H, Zeiler H-J (1990) Chemotherapy of experimental Mycoplasma pneumoniae infection in hamsters and host response. In: Stanek G, Cassell GH, Tully J, Whitcomb RF (eds) Recent advances in mycoplasmology. Fischer, Stuttgart, pp 83-90
12. Bale MF, Chandler DKF, Yoshida H, Grabowski MW, Harasawa R, Razin S (1988) Parameters of Mycoplasma pneumoniae infection in Syrian hamsters. Infect Immun 56: 2443-2449
13. Barile MF, Grabowski MW, Snoy PJ, Chandler DKF (1987) Superiority of the chimpanzee animal model to study the pathogenicity of known Mycoplasma pneumoniae and reputed mycoplasma pathogens. Isr J Med Sci 23: 556-560
14. Liu C, Jayanetra P, Voth DW, Muangmanee L, Cho CT (1972) Potentiating effect of Mycoplasma pneumoniae infection on the development of pneumococcal septiccmia in hamsters. J Infect Dis 125: 603-612
15. Cimolai N, Wensley D, Seear M, Thomas ET (1995) Mycoplasma pneumoniae as a cofactor in severe respiratory infections. Clin Infect Dis 21: 1182-1185
16. Brunner H (1993) Mycoplasma infections of man: respiratory and male genital tract diseases. In: Kahane I, Adoni A (eds) Rapid diagnosis of mycoplasmas. Plenum Press, New York London, pp 39-56
17. Brunner H, Prescott B, Greenberg H, James WD, Horswood RL, Chanock RM (1977) Unexpectedly high frequency of antibody to Mycoplasma pneumoniae in human sera as measured by sensitive techniques. J Infect Dis 135: 524-530
18. Smith CB, Friedewald WT, Alford RH, Chanock RM (1967) Mycoplasma pneumoniae infections in volunteers. NY Acad Sci 143: 471-483
19. Brunner H, Prescott B (1982) Effect of Mycoplasma pneumoniae polysaccharides, and glycolipids on prophylaxis of experimental disease. In: Weinstein L, Fields B (eds) Seminars in infectious diseases, vol 4. Bacterial vaccines. Thieme Stratton Inc., New York, pp 190-197
20. Jacobs E, Stuhlert A, Drews M, Pumpe K, Schaefer HE, Kist M, Bredt W (1988) Host reactions to Mycoplasma pneumoniae infections in guinea pigs preimmunized systemically with the adhesions of this pathogen. Microbial Pathogen 5: 259-265
21. Brunner H, Greenberg HB, James WD, Horswood RL, Couch RB, Chanock RM (1973) Antibody to Mycoplasma pneumoniae in nasal secretions and sputa of experimentally infected human volunteers. Infect Immun 8: 612-620
22. Loos M, Brunner H (1979) Complement components (C1, C2, C3, C4) in bronchial secretions after intranasal infection of guinea pigs with Mycoplasma pneumoniae: dissociation of unspecific and specific defense mechanisms. Infect Immun 25: 583-585
23. Brunner H, Greenberg HB, James WD, Horswood RL, Chanock RM (1973) Decreased virulence and protective effect of genetically stable temperature-sensitive mutants of Mycoplasma pneumoniae. Ann Y Acad Sci 225: 436-452
24. Brunner H, Weidner W (1981) Chemotherapy of human mycoplasma diseases. Isr J Med Sci 17: 656-660
25. Sabato AR, Cooper DM, Thong YH (1981) Transitory depression of immune function following Mycoplasma pneumoniae infection in children. Pediatr Res 15: 813-816
26. Brunner H, Weidner W, Schiefer HG (1983) Studies on the role of Ureaplasma urealyticum and Mycoplasma hominis in prostatitis. J Infect Dis 147: 807-813
27. Mardh P-A (1983) Mycoplasma PID: a review of natural and experimental infections. Yale J Biol Med 56: 529-536
28. Taylor-Robinson D, Furr PM (1993) Models of infection due to mycoplasmas. including Mycoplasma fermentans, in the genital tract and other sites in mice. Clin Infect Dis 17 [Suppl] 1: 280-282
29. Furr PM, Taylor-Robinson D (1996) Observations on immunity and effect of antibiotics in murine models of Mycoplasma pneumoniae respiratory and genital infection. IOM Letters 4: 22
30. Yánez A, Martinez A, Calixto T, Nino G, Gil C, Hernández-Jauregui P, Cedillo L (1996) Experimental respiratory tract infection by Mycoplasma fermentans in hamsters. IOM Letters 4: 348